Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.90 [0.78, 1.04] | | < 1 | | 0% | 2 studies (2/-) | 92.9 % | some concern | not evaluable | moderate | crucial | - |
progression or deaths (PFS) | 1.10 [0.95, 1.27] | | < 1 | | 0% | 2 studies (2/-) | 9.7 % | some concern | not evaluable | moderate | important | - |
objective responses (ORR) | 1.54 [1.12, 2.12] | | > 1 | | 0% | 2 studies (2/-) | 99.6 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
STRAE (any grade) | 0.37 [0.24, 0.57] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.29 [0.21, 0.42] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.12 [0.08, 0.18] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.19 [0.05, 0.68] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.47 [0.29, 0.77] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Acute kidney injury TRAE (grade 3-4) | 0.93 [0.02, 46.93] | | < 1 | | 0% | 1 study (1/-) | 51.4 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 1.86 [0.06, 55.60] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 0.93 [0.02, 46.93] | | < 1 | | 0% | 1 study (1/-) | 51.4 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.03 [0.00, 0.44] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.46 [0.02, 13.86] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.06 [0.01, 0.49] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 3.73 [0.17, 82.97] | | < 1 | | 0% | 1 study (1/-) | 20.6 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.07 [0.00, 1.15] | | < 1 | | 0% | 1 study (1/-) | 96.7 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.11 [0.01, 2.18] | | < 1 | | 0% | 1 study (1/-) | 92.3 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 0.46 [0.04, 5.13] | | < 1 | | 0% | 1 study (1/-) | 73.3 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.09 [0.01, 0.71] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.01 [0.00, 0.20] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Headache TRAE (grade 3-4) | 0.46 [0.02, 13.86] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
Hypersensitivity TRAE (grade 3-4) | 0.46 [0.02, 13.86] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
Hypertension TRAE (grade 3-4) | 1.86 [0.17, 20.62] | | < 1 | | 0% | 1 study (1/-) | 30.8 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.86 [0.06, 55.60] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 3.73 [0.17, 82.97] | | < 1 | | 0% | 1 study (1/-) | 20.6 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 3.74 [0.42, 33.65] | | < 1 | | 0% | 1 study (1/-) | 12.1 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 5.64 [0.68, 47.10] | | < 1 | | 0% | 1 study (1/-) | 5.6 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.05 [0.00, 0.78] | | < 1 | | 0% | 1 study (1/-) | 98.3 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.11 [0.01, 2.18] | | < 1 | | 0% | 1 study (1/-) | 92.3 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Myocarditis TRAE (grade 3-4) | 0.93 [0.02, 46.93] | | < 1 | | 0% | 1 study (1/-) | 51.4 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.01 [0.00, 0.13] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.46 [0.02, 13.86] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Peripheral oedema TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Peripheral sensory neuropathy TRAE (grade 3-4) | 0.46 [0.02, 13.86] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
Pneumonia TRAE (grade 3-4) | 0.09 [0.00, 1.68] | | < 1 | | 0% | 1 study (1/-) | 94.4 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 2.80 [0.29, 27.04] | | < 1 | | 0% | 1 study (1/-) | 18.8 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.93 [0.02, 46.93] | | < 1 | | 0% | 1 study (1/-) | 51.4 % | NA | not evaluable | | non important | - |
Sepsis TRAE (grade 3-4) | 0.23 [0.01, 5.14] | | < 1 | | 0% | 1 study (1/-) | 82.0 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 0.93 [0.06, 14.90] | | < 1 | | 0% | 1 study (1/-) | 52.1 % | NA | not evaluable | | non important | - |